Adjuvant Versus Neo-adjuvant Radiotherapy in Patients With Resectable Soft Tissue Sarcoma in Extremities : Wound Complications

NCT ID: NCT05442333

Last Updated: 2023-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Extremity soft tissue sarcomas (ESTS)s are rare mesenchymal cancers that considered a challenge for orthopaedic surgeons. Soft tissue sarcomas (STS) comprise less than 1% of malignant cancers, commonly occur in the proximal extremities and trunk. Limb-sparing surgery mostly are targeted in most of the patients, so adjuvant or neoadjuvant radiotherapy is usually added. Preoperative radiotherapy (neoadjuvant) or postoperative radiotherapy (adjuvant) offers local control and survival rates, but the local complications are controversial. However, different retrospective studies had shown that preoperative radiotherapy cause higher wound complication rate, while both preoperative and postoperative radiotherapy had the same results regarding local recurrence

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Tools :The patients will be managed as follows:

Primary (Preoperative) Diagnosis and Evaluation

Clinical Evaluation. History. General examination. Local examination.

Radiological Evaluation:

Plain X-ray for the affected limb to determine presence of any bone affection or invasion.

Preoperative MRI scan to determine the extent of soft tissue, bone and neurovascular bundle invasion.

Preoperative bone scan to determine skeletal metastatic load.

Perioperative protocol:

Preoperative radiotherapy 3-6 weeks before surgical excision. Postoperative radiotherapy 3- 6 weeks or more after surgical excision Tissue diagnosis will be obtained.

Operative management:

Surgical excision of whole tumour with wide safety margin.

Data collection:

Patient demographics (age, sex). Activity level Primary sarcoma type Patient comorbidities Timing of Preoperative radiotherapy if present. Timing of Postoperative radiotherapy if present. Time from diagnosis to surgery. recurrence Operative time (minutes) measured from skin incision to wound closure. Follow up regarding wound complications, local recurrence or infection. local recurrence will be followed up till the end of the study

Follow up strategy:

The patients with preoperative radiotherapy:

will be assessed 2 weeks postoperative regarding wound signs of infection (redness, hotness or discharge).

1 month postoperatively for wound complete closure and exclude signs of infection.

3 months postoperatively for wound dehiscence, swelling or local recurrence. 6 months postoperatively for local recurrence, pathological fractures or joint stiffness

The patients with postoperative radiotherapy:

will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).

6 weeks post radiation for wound dehiscence 3 months post radiation for local swelling or recurrence 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

Statistical Analysis: Statistical package for social science (SPSS 15.0.1 for windows ; 〖SPSS Inc,Chicago,IL,2001). Data will be presented as Mean and Standard deviation ( +/-SD) for quantitative parametric data , and Median and Interquartile range for quantitative non parametric data. Frequency and percentage will be used for presenting qualitative data. Suitable analysis will be done according to the type of data obtained. P\<0.05 will be considered significant.

Statistical Package: data entry and statistical analysis of the collected data will be performed using reliable software program.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resectable Soft Tissue Sarcoma Extremities Radiotherapy Wound Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

preoperative radiotherapy

The patients which will receive preoperative radiotherapy

Group Type ACTIVE_COMPARATOR

surgical resection with safety margin

Intervention Type PROCEDURE

• The patients with preoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

The patients with postoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

postoperative radiotherapy

The patients which will receive postoperative radiotherapy

Group Type ACTIVE_COMPARATOR

surgical resection with safety margin

Intervention Type PROCEDURE

• The patients with preoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

The patients with postoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

surgical resection with safety margin

• The patients with preoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

The patients with postoperative radiotherapy:

1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).
2. 6 weeks post radiation for wound dehiscence
3. 3 months post radiation for local swelling or recurrence
4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pre operative radiotherapy post operative radiotherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sex: both sexes.
* Lesion: any soft tissue sarcoma in upper or lower limbs (synovial sarcoma, liposarcoma, fibrosarcoma and others)
* age more than 16 years old

Exclusion Criteria

* Irresectable ESTS
* Round cell ESTS
* recurrent ESTS
* patients who received local irradiation due to other causes
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ziad Khaled Abdullah Abdul Qader

orthopedic oncology department assistant lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University Hospitals

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ziad khaled

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hypofractionated Radiotherapy for Soft Tissue Sarcomas
NCT03972930 ACTIVE_NOT_RECRUITING PHASE2
Pre-operative RadiothErapy for Soft Tissue SarcOmas
NCT04617327 ACTIVE_NOT_RECRUITING NA